These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32024754)

  • 1. TIP5 primes prostate luminal cells for the oncogenic transformation mediated by
    Pietrzak K; Kuzyakiv R; Simon R; Bolis M; Bär D; Aprigliano R; Theurillat JP; Sauter G; Santoro R
    Proc Natl Acad Sci U S A; 2020 Feb; 117(7):3637-3647. PubMed ID: 32024754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence.
    Manda KR; Tripathi P; Hsi AC; Ning J; Ruzinova MB; Liapis H; Bailey M; Zhang H; Maher CA; Humphrey PA; Andriole GL; Ding L; You Z; Chen F
    Oncogene; 2016 Jun; 35(25):3282-92. PubMed ID: 26477312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome.
    Li Y; Su J; DingZhang X; Zhang J; Yoshimoto M; Liu S; Bijian K; Gupta A; Squire JA; Alaoui Jamali MA; Bismar TA
    J Pathol; 2011 May; 224(1):90-100. PubMed ID: 21381033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BAZ2A-mediated repression via H3K14ac-marked enhancers promotes prostate cancer stem cells.
    Peña-Hernández R; Aprigliano R; Carina Frommel S; Pietrzak K; Steiger S; Roganowicz M; Lerra L; Bizzarro J; Santoro R
    EMBO Rep; 2021 Nov; 22(11):e53014. PubMed ID: 34403195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis.
    Bai Y; Yang Y; Yan Y; Zhong J; Blee AM; Pan Y; Ma T; Karnes RJ; Jimenez R; Xu W; Huang H
    Theranostics; 2019; 9(12):3459-3475. PubMed ID: 31281490
    [No Abstract]   [Full Text] [Related]  

  • 6. MEX3D is an oncogenic driver in prostate cancer.
    Shao L; Wang J; Karatas O; Ittmann M
    Prostate; 2021 Nov; 81(15):1202-1213. PubMed ID: 34455614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional landscape of PTEN loss in primary prostate cancer.
    Imada EL; Sanchez DF; Dinalankara W; Vidotto T; Ebot EM; Tyekucheva S; Franco GR; Mucci LA; Loda M; Schaeffer EM; Lotan T; Marchionni L
    BMC Cancer; 2021 Jul; 21(1):856. PubMed ID: 34311724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay.
    Park JW; Lee JK; Phillips JW; Huang P; Cheng D; Huang J; Witte ON
    Proc Natl Acad Sci U S A; 2016 Apr; 113(16):4482-7. PubMed ID: 27044116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer.
    Ding Y; Li N; Dong B; Guo W; Wei H; Chen Q; Yuan H; Han Y; Chang H; Kan S; Wang X; Pan Q; Wu P; Peng C; Qiu T; Li Q; Gao D; Xue W; Qin J
    J Clin Invest; 2019 Feb; 129(2):759-773. PubMed ID: 30496141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
    Xing C; Ci X; Sun X; Fu X; Zhang Z; Dong EN; Hao ZZ; Dong JT
    Neoplasia; 2014 Nov; 16(11):883-99. PubMed ID: 25425963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LZTS2 and PTEN collaboratively regulate ß-catenin in prostatic tumorigenesis.
    Yu EJ; Hooker E; Johnson DT; Kwak MK; Zou K; Luong R; He Y; Sun Z
    PLoS One; 2017; 12(3):e0174357. PubMed ID: 28323888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.
    Lu W; Liu S; Li B; Xie Y; Izban MG; Ballard BR; Sathyanarayana SA; Adunyah SE; Matusik RJ; Chen Z
    Oncogene; 2017 Mar; 36(10):1364-1373. PubMed ID: 27869166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative analysis of a panel of gene expression in prostate cancer--with emphasis on NPY expression analysis.
    Liu AJ; Furusato B; Ravindranath L; Chen YM; Srikantan V; McLeod DG; Petrovics G; Srivastava S
    J Zhejiang Univ Sci B; 2007 Dec; 8(12):853-9. PubMed ID: 18257117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of lncRNAs in prostate cancer development and progression.
    Weiss M; Plass C; Gerhauser C
    Biol Chem; 2014 Nov; 395(11):1275-90. PubMed ID: 25153594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice.
    Lu TL; Huang YF; You LR; Chao NC; Su FY; Chang JL; Chen CM
    Am J Pathol; 2013 Mar; 182(3):975-91. PubMed ID: 23313138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma).
    Shah RB; Shore KT; Yoon J; Mendrinos S; McKenney JK; Tian W
    Prostate; 2019 Aug; 79(11):1267-1273. PubMed ID: 31111513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence.
    Gu L; Frommel SC; Oakes CC; Simon R; Grupp K; Gerig CY; Bär D; Robinson MD; Baer C; Weiss M; Gu Z; Schapira M; Kuner R; Sültmann H; Provenzano M; ; Yaspo ML; Brors B; Korbel J; Schlomm T; Sauter G; Eils R; Plass C; Santoro R
    Nat Genet; 2015 Jan; 47(1):22-30. PubMed ID: 25485837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.
    Li N; Xue W; Yuan H; Dong B; Ding Y; Liu Y; Jiang M; Kan S; Sun T; Ren J; Pan Q; Li X; Zhang P; Hu G; Wang Y; Wang X; Li Q; Qin J
    J Clin Invest; 2017 Apr; 127(4):1284-1302. PubMed ID: 28319045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DGCR8 is essential for tumor progression following PTEN loss in the prostate.
    Belair CD; Paikari A; Moltzahn F; Shenoy A; Yau C; Dall'Era M; Simko J; Benz C; Blelloch R
    EMBO Rep; 2015 Sep; 16(9):1219-32. PubMed ID: 26206718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
    Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
    Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.